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 Abstract. Many viruses have been investigated for their
oncolytic properties and potential use as therapeutic agents
for cancer treatment. Most of these replication-competent
viruses are human pathogens. We investigated the oncolytic
properties of an animal virus which is non pathogenic for
both its natural host and humans. Bovine enterovirus has
previously been shown to exhibit a very wide tissue tropism for
cell types in vitro. We compare the ability of bovine
enterovirus to replicate in and to cause cytopathic effect in
freshly isolated human monocytes and monocyte derived
macrophages with the monocyte-like U937 tumour cell line.
We also include the adherent ZR-75-1 human breast cancer
cell line. We have also carried out infections of bovine entero-
virus in the presence and in the absence of serum of bovine
origin. Our study shows that the virus will replicate in and
produce cytopathic effect in the U937 and ZR-75-1 cell types
to the same extent as the cells (BHK-21) in which the virus is
routinely propagated. We believe bovine enterovirus to be a
worthwhile candidate for further study as an anti-tumour agent.
Introduction
Most viruses are characterised by a well defined tissue tropism
constrained by the presence of specific cell surface receptors.
Bovine enterovirus (BEV), a picornavirus of the genus
enterovirus, is an exception. Endemic in cattle populations
but non-pathogenic (1), BEV may be routinely isolated from
faecal samples (2). The bovine enteroviruses have been
classified into two serotypes (3), the most extensively studied
of which is serotype 1, subtype 1. We have previously solved
the crystal structure of this virus (4) and determined the
structural basis for serotype specificity (5).
Various attempts have been made to determine the cell
surface receptor for BEV, but efforts have been thwarted by
the extensive range of cell types in which cytopathic effect may
be demonstrated in vitro. BEV is routinely cultured in baby
hamster kidney (BHK-21) cells, yet is commonly known to
be readily adaptable to grow in the HeLa, human cervical
carcinoma cell line, to equivalent titre. The virus has also been
shown to cause no detectable pathogenic effect across a
range of rodents (unpublished data). Attachment of BEV to
the cellular receptor has been shown to be sensitive to
neuraminidase (6). The receptors are known in the case of the
major group human rhinoviruses to be ICAM-1 (7), for FMDV
to be ·vß3 (8) and the coxsackieviruses which can use two
different receptors: coxsackie and adenovirus receptor (CAR)
and decay accelerating factor (DAF) (9,10). However in the
case of BEV the receptor must be a ubiquitous cell surface
glycoprotein sharing structural homology with ICAM-1 and
PVR as the crystal structure of BEV reveals its surface
features to be similar to those viruses using these receptors.
In recent years viruses have been used for cancer therapy
as alternatives to traditional methods where these are not
effective. Examples of the replication-competent viruses
currently being employed or investigated include vaccinia
virus, reovirus, autonomous parvovirus and Newcastle disease
virus (reviewed in ref. 11). Other viruses such as herpes
simplex virus are being investigated in their replication
deficient forms as vectors for anti-tumour agents (12,13) and
suicide genes (14).
We wished to further characterise and study the oncolytic
properties of BEV because detailed studies have not been
reported since the early 1970s when it was observed that BEV
could replicate in a variety of normal and tumour cells (15,16).
Furthermore it has been shown that treatment with BEV could
cause regression of solid and ascites tumours in rodents (17).
We examined and characterised the ability of BEV to
successfully infect and produce cytopathic effect in human
cells. We have chosen to investigate the monocyte-like U937
tumour cell line in order to facilitate a direct comparison with
its corresponding normal counterpart, freshly isolated human
monocytes and also monocyte-derived macrophages. To
address possible differences in adherent and suspension
cultures we have included the adherent ZR-75-1 human breast
cancer cell line in the study. Finally, although the cells are of
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human origin they are all maintained in medium supplemented
with serum of bovine origin. We therefore investigated possible
effects of FCS on virus growth in human cells.
Materials and methods
Materials. Nycodenz-M was from Nycomed AS (Oslo,
Norway). All other chemicals were from Sigma Chemical
Company (Poole, UK).
Cell culture. BHK-21 (clone 13) hamster syrian kidney cells
(ECACC, Porton Down, Salisbury, England) were routinely
maintained in GMEM medium supplemented with FCS (10%),
penicillin (50 IU/ml), streptomycin (50 µg/ml), glutamine
(300 µg/ml), and tryptose phosphate broth (5%). The histio-
cytic lymphoma monocyte-like U937 cell line (18) and the
ZR-75-1 human breast cancer cell line (19) (ECACC, Porton
Down, Salisbury, England) were routinely maintained in
RPMI 1640 medium supplemented with HEPES (20 mM), FCS
(10%), penicillin (50 IU/ml), streptomycin (50 µg/ml), and
glutamine (300 µg/ml). Cells were grown in 5% CO2 at 37˚C.
Preparation and culture of monocytes and monocyte-derived
macrophages. Monocytes were isolated from heparinized
venous blood of healthy volunteers using a combined dextran/
Nycodenz-M separation procedure (20) as detailed in Davies
and Edwards (21). Monocytes (>95% purity) were suspended
in RPMI 1640 medium supplemented with HEPES (20 mM),
FCS (10%), penicillin (50 IU/ml), streptomycin (50 µg/ml)
and glutamine (300 µg/ml). Cells were enumerated using a
haemocytometer slide. Monocytes (8x104) were plated into
microtitre plates and cultured at 37˚C. Following 6 days in vitro
they are then referred to as monocyte-derived macrophages.
Cell viability (trypan blue exclusion) was >98% throughout
the period of culture.
Virus maintainance. Bovine enterovirus type 1 (ATCC,
Rockville, MD, USA) was routinely propagated in BHK-21
cells. Medium was removed from confluent BHK-21 cell
monolayers and the cell sheet rinsed with PBS. Previous virus
harvest was added 1 ml per 175 cm2 cell area. The inoculum
was incubated on the cell sheet for 30 min at 37˚C with
gentle rocking to allow optimum distribution. The monolayer
was covered with serum-free medium and incubated for 16 h
at 37˚C. Virus was harvested and stored at -20˚C.
Growth of virus in human cells. BEV was added to freshly
isolated monocytes, monocyte-derived macrophages, U937
cells or ZR-75-1 cells to give a moi of 1.5. Following 16 h
incubation at 37˚C, cells were subjected to a freeze/thaw cycle
and spun at 2000 rpm for 4 min. The supernatant was stored
at -20˚C for later titration.
Virus titration. BHK-21 cells were grown until confluent in
24-well culture plates. A 10-fold dilution series of each virus
sample to be titrated was made in serum-free medium and
200 µl of each dilution was inoculated onto each monolayer in
duplicate. Virus was adsorbed at 37˚C for 30 min with rocking.
The inoculum was removed, the cells washed with PBS and
overlaid with 1 ml of agar prepared as follows: a 1.5% (w/v)
solution of agar Noble was autoclaved, cooled to 45˚C and an
equal volume of double strength serum-free medium. Overlaid
monolayers were incubated at 37˚C for 3 days. One ml of cell
fixative and stain (20% v/v ethanol, 10% v/v formalin and
0.7% v/v 0.25 M KOH in water) was added and allowed to
diffuse through the agar for 2 h before carefully removing the
agar. Plaques were counted and the virus titre expressed as
plaque forming units per ml (pfu/ml).
Results
Normal in vitro infectivity. Bovine enterovirus type 1 is
routinely maintained in BHK-21 cells. Fresh virus seed from
the ATCC stock, stored at -70˚C, reproducibly grows to a titre
in the range 2x108-2.5x108 pfu/ml. Repeated passage followed
by storage of the virus harvest at -20˚C causes this titre to fall
by approximately two logarithmic units (unpublished).
Cytopathic effect in fibroblastic cells is observed within 8 h
post-infection as rounding up of the cells and loss of adherence.
In addition, the cytoplasm becomes distinctly granular in
appearance as viewed using phase contrast microscopy. When
infected at moi of 1.5, all cells show this cytopathic effect after
the second round of infection at 16 h. Using this information
and previous discontinued reports that BEV exhibits oncolytic
properties (15,16) we wished to determine, characterise and
quantify this effect in human cells.
Infectivity in human cells cultured in bovine serum. To
investigate possible oncolytic properties of BEV in human cells
we infected freshly isolated human monocytes, monocyte-
derived macrophages, the U937 histiocytic lymphoma
monocyte-like, and ZR-75-1 human breast cancer cell lines,
with the virus. Each infection was carried out at moi of 1.5 in
the presence of FCS. Observation of the cells was carried out
at hourly intervals in order that the onset and extent of any
cytopathic effect could be noted. Medium containing any
progeny virus was harvested at 16 h post-infection and titrated
by plaque assay on BHK-21 cells also in the presence of FCS.
Virus infection was detected by the onset of cytopathic
effect in the U937 cells and the ZR-75-1 cells at between 6
and 7 h post-infection. Fig. 1 shows U937 cells prior to
infection and following the onset of cytopathic effect. Fig. 2
shows the same in the case of ZR-75-1 cells. The time of this
observation was the same as for BEV-infected BHK-21 cells.
Cytopathic effect in human monocytes and human monocyte-
derived macrophages as shown in Table I was slight by
comparison so was only observed much later in the infection
cycle. Table I also shows the results of the titration of the
supernatant from each infection. Virus replicated efficiently
in both human tumour cell lines, giving titres equivalent to
that grown in BHK-21 cells. Virus progeny from the infection
of monocyte-derived macrophages was some two orders of
magnitude lower. However, growth in the freshly isolated
human monocytes gave equivalent numbers of pfu per unit
volume as from BHK-21 cells.
Infectivity in human cells cultured in the absence of bovine
serum. As BEV is not known to produce any disease in humans
it is of interest that the results in Table I demonstrate that BEV
grows to an equivalent titre in freshly isolated human mono-
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cytes compared to BHK-21 cells which are routinely used for
its propagation. Although the monocytes are of human origin,
following their isolation from venous blood, they are cultured
in medium which is supplemented with serum of bovine
origin. Therefore further experiments were carried out with
freshly isolated human monocytes which were cultured in the
absence of FCS. In addition BHK-21 cells were infected in
the absence of the bovine serum, although the cells had
previously been cultured in FCS. It was not possible to infect
monocyte-derived macrophages under the same conditions as
they do not survive in vitro without FCS. In addition, U937
and ZR-75-1 cells are routinely cultured in medium
containing bovine serum and therefore were not suitable for
this part of the study.
The onset of cytopathic effect in the BHK-21 cells was
observed as normal at 6-7 h post-infection while again as
shown in Table II the effect of the cytopathic effect in the
human monocytes was slight and not detected for 2-3 more
hours. Table II shows the results of the titration from
infection of BHK-21 cells and human monocytes in the
absence of FCS. Virus replicated in BHK-21 cells in the
absence of FCS, giving titres equivalent to that grown in BHK-
21 cells in the presence of FCS. However, virus progeny from
the infection of monocytes in the absence of FCS was some
two orders of magnitude lower in pfu per unit volume than for
monocytes in the presence of FCS. All plaque assay titrations
were carried out on BHK-21 cells in the presence of bovine
serum.
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Figure 1. Effect of BEV infection on ZR-75-1 human breast cancer cells.
A, appearance of ZR-75-1 cells before infection with BEV. B, cytopathic
effect in ZR-75-1 cells 16 h post-infection with BEV.
Figure 2. Effect of BEV infection on monocyte-like U937 tumour cells.
A, appearance of U937 cells before infection with BEV. B, cytopathic effect
in U937 cells 16 h post-infection with BEV.
Table I. Effect of BEV infection on various cell types.a
–––––––––––––––––––––––––––––––––––––––––––––––––
Cell type Cytopathic effect Titre (pfu/ml)
–––––––––––––––––––––––––––––––––––––––––––––––––
BHK-21 +++ 2.5x106
Human monocytes + 2.5x106
U937 +++ 2.5x106
Human monocyte-
derived macrophages + 1.0x104
ZR-75-1 +++ 2.5x106
–––––––––––––––––––––––––––––––––––––––––––––––––
aCytopathic effect was scored as follows, + slight, ++ moderate,
+++ severe, as observed 16 h post infection. Titres shown are of virus
harvested from 16 h infections of various cell types. Each experiment
was carried out in the presence of FCS at a multiplicity of infection
(moi) of 1.5 and all titrations were carried out by plaque assay on
BHK-21 cells.
–––––––––––––––––––––––––––––––––––––––––––––––––
Table II. Effect of BEV infection on BHK-21 and human
monocyte cells in the absence of FCS.a
–––––––––––––––––––––––––––––––––––––––––––––––––
Cell type Cytopathic effect Titre (pfu/ml)
–––––––––––––––––––––––––––––––––––––––––––––––––
BHK-21 +++ 2.5x106
Human monocytes + 1.0x104
–––––––––––––––––––––––––––––––––––––––––––––––––
aCytopathic effect was scored as follows, + slight, +++ severe, as
observed 16 h post infection. Titres shown are of virus harvested
from 16 h infections of various cell types. Each experiment was
carried out at a multiplicity of infection (moi) of 1.5 and all titrations
were carried out by plaque assay on BHK-21 cells in the presence
of FCS.
–––––––––––––––––––––––––––––––––––––––––––––––––
A
B
A
B
Discussion
BEV has a rare property among the animal viruses in that it
has an extremely wide tissue tropism yet is not known to be a
pathogen in any system. It is endemic in cattle populations
worldwide but is unknown in humans, even those in close
proximity with cattle. In this study we wished to investigate
and evaluate the ability of BEV to replicate in normal human
cells and their tumour counterparts.
BEV is routinely grown and cultured in BHK-21 cells
which are in turn cultured in bovine serum. The first part of
the investigation compared the cytopathic effect and titre of
virus progeny of BEV infected human cells with the BHK-21
(Table I). At 16 h post infection the U937 and ZR-75-1 cells
showed dramatic cytopathic effect (Figs. 1 and 2
respectively) comparable with that produced in BHK-21 cells.
However, the human monocytes and human monocyte-
derived macrophages showed very little cytopathic effect.
When the titres of the virus progeny were determined by
plaque assay on BHK-21 cells the only cell type to produce a
titre lower than that normally seen from BHK-21 cells was
the human monocyte-derived macrophages.
The fact that BEV can replicate in such a wide range of
cell types must at least in part be due to its ability to use a
receptor or range of receptors which are present on each of
these cells. It has been shown in the case of FMDV that
mutations in its receptor binding site, which is an RGD motif,
are lethal for field isolates (22) but they are not lethal for
FMDV serotypes routinely maintained in tissue culture (23).
Hence as this virus apparently adapts in tissue culture to use
other receptor binding sites it is possible that BEV has also
adapted in such a manner. Once inside the cell BEV, along
with all other enteroviruses, shuts down host protein, RNA
and DNA synthesis. However, as the rapidity of the inhibition
is dependent on the host cell type (24) then this may explain
the variation in the titres of the virus progeny. Furthermore,
such a variation may account for the late observation of onset
of cytopathic effect in the monocytes and monocyte-derived
macrophages.
Each of these cell types had been cultured and routinely
maintained in medium supplemented with serum of bovine
origin. It is possible that a factor present in the serum may
mediate between the cellular receptor and the virus receptor
binding site. Such accessory molecules have been identified in
the attachment of other viruses. Several of the herpes viruses
have been shown to use heparin sulphate as an accessory which
enhances the efficiency of an internalisation receptor following
initial attachment (25). In order to determine whether a
component in the bovine serum was acting in such a manner
it was necessary to infect cells which had never been exposed
to bovine serum. Table II shows the results of freshly isolated
human monocytes infected with BEV in the absence of bovine
serum. The slight cytopathic effect was comparable to the
same cell type in the presence of bovine serum but the titre of
virus progeny was reduced by more than 100-fold. These
results indicate that there is indeed a factor present in the
bovine serum which enhances infectivity. It was not possible
to infect tumour cells in the same way as all such cell types
in our laboratory have been routinely cultured in medium
containing bovine serum. However, a previous study showed
that mice bearing ascites tumour sarcoma 180 and treated
with BEV showed little or no histological change other than
the lysis of the tumour cells (16).
While much work remains to be carried out on BEV's
oncolytic properties, clearly the results shown here together
with previous discontinued studies (15,17) indicate the virus to
be worthy of inclusion with those viruses being investigated
for cancer therapy.
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